Deal or Case news
Sanofi, a global leader in healthcare, and Kiadis Pharma N.V., a Dutch biotechnologist listed on Euronext Amsterdam and Brussel, announced their agreement on a recommended public offer for all outstanding Kiadis shares at an offer price of EUR 5.45, valuing the company at approximately EUR 308 million.

The offer price represents an extraordinary premium of 272% over the closing price of Kiadis’ shares as of 30 October 2020.

Kiadis’ proprietary platform is based on allogeneic or ‘off-the-shelf' NK-cells from a healthy donor. NK-cells seek and identify malignant cancer cells and have broad application across various tumor types. The platform has the potential to make products rapidly and economically available for a broad patient population across a wide range of indications. Kiadis’ NK cell-based medicines will be developed alone and in combination with Sanofi’s existing platforms.

Sanofi is a longstanding client of NautaDutilh, in particular with our office in Brussels. Our role on this transaction underlines the benefit of our offering of a broad range of legal services throughout the Benelux.

The team was led by Leo Groothuis and further consisted of: Ruud Smits, Philippe Remels, Sybren de Beurs, Jos Somers, Eva van Rooijen, Dineth de Graaf, Mariska Ramdhani-Kamta and Thomas Castermans (Corporate M&A), David Viëtor and Linda Tomassen (Finance), Nina Kielman (Tax), Paul van der Bijl and Koen Biesma (Corporate notarial) and Jeroen Boelens (IP/Pharma).

Related articles

Cookie notification

This functionality uses third-party cookies. Change your cookie preferences to view this content or view more information.
These cookies ensure that the website works properly. These cookies cannot be disabled.
These cookies can be placed by third parties, such as YouTube or Vimeo.
By deactivating categories, it is possible that related functionalities within the website may no longer work properly. It is always possible to change your preferences at a later time. View more information.